Mitapivat
295 interactions 80 cited referencesMitapivat is used to treat hemolytic anemia (a blood disorder that occurs when red blood cells are destroyed faster than they can be made in the body) in people with pyruvate kinase deficiency. Mitapivat is in a class of medications called pyruvate kinase activators. It works by increasing pyruvate kinase available to… Read the full Mitapivat drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Mitapivat Tipranavir Aptivus Reduced CYP3A substrate exposure Details Mitapivat Tolvaptan Jynarque Increased P-gp substrate exposure; reduced CYP3A substrate exposure Details Mitapivat Tramadol ConZip Reduced traMADol exposure and reduced efficacy of traMADol Details Mitapivat Treosulfan Grafapex Increased mitapivat exposure Details Mitapivat Triazolam Halcion Reduced CYP3A substrate exposure Details Mitapivat Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Mitapivat Troleandomycin Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Tucatinib Tukysa Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Ubrogepant Ubrelvy Reduced CYP3A substrate exposure Details Mitapivat Ulipristal Ella Reduced hormonal contraceptive exposure Details Mitapivat Vanzacaftor Reduced vanzacaftor exposure and reduced efficacy of vanzacaftor Details Mitapivat Vardenafil Levitra Reduced CYP3A substrate exposure Details Mitapivat Venetoclax Venclexta Reduced CYP3A substrate exposure Details Mitapivat Verapamil Calan Increased mitapivat exposure Details Mitapivat Voclosporin Lupkynis Reduced CYP3A substrate exposure Details Mitapivat Vonoprazan Voquezna Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Voriconazole Vfend Increased mitapivat exposure, an increased risk of mitapivat-related adverse effects, reduced voriconazole exposure and an reduced... Details Mitapivat Voxelotor Oxbryta Increased mitapivat exposure Details Mitapivat Warfarin Coumadin Reduced CYP3A/CYP2C9 substrate exposure Details Mitapivat Zanubrutinib Brukinsa Reduced zanubrutinib exposure and reduced efficacy of zanubrutinib Details Mitapivat Ziftomenib Komzifti Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Mitapivat Nafcillin Injection Unipen® Injection Reduced mitapivat exposure and reduced efficacy of mitapivat DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist